Eli Lilly has indicated that the broader TRIUMPH program, which includes trials in obesity (TRIUMPH-1), type 2 diabetes (TRIUMPH-2 and TRIUMPH-3), and obesity-related conditions (TRIUMPH-4), is progressing on schedule
Supplemental NAD+ boosts cellular repair, recovery, and cognitive clarity
Understanding the interactions between ibuprofen and microplastics and their combined effects on freshwater ecosystems is crucial for predicting long-term environmental consequences
Case Series: A six-patient case series investigates adjustments to background therapies and glycemic outcomes surrounding the initiation and titration of long-acting glucagon-like peptide 1 receptor agonists (GLP-1 RAs) to shed light on practical methods to manage patient care during this tenuous phase
This stack is ideal for high-performance professionals, athletes, and anyone looking to stay sharp and focused
Obesity has been linked to an increased risk of several types of cancer, including breast, colon, and endometrial cancer